Loading
A phase 3 trial testing JMT101 in non-small-cell lung cancer, now recruiting.
A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations is a phase 3 interventional study registered as NCT06735391, led by Shanghai JMT-Bio, and recruiting on the registry. Official title: A Phase 3 Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations. Planned enrolment is 516 participants (estimated). The study started in 2024-10-23 and primary completion is expected in 2026-09-30. No results have been posted on ClinicalTrials.gov.
Shares CSPC Pharmaceutical Group, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer.
Shares CSPC Pharmaceutical Group, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer.
Shares CSPC Pharmaceutical Group, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer.
Shares CSPC Pharmaceutical Group, EGFR-mutated non-small-cell lung cancer.
Shares CSPC Pharmaceutical Group, EGFR-mutated non-small-cell lung cancer.
Shares CSPC Pharmaceutical Group, Non-small-cell lung cancer.
Shares CSPC Pharmaceutical Group, Non-small-cell lung cancer.
Shares CSPC Pharmaceutical Group, Non-small-cell lung cancer.